ClinicalTrials.gg
CompletedNCT01707134Updated Jan 4, 2017

Safety and Efficacy of Insulin Aspart in Subjects With Type 1 Diabetes

A Phase 3 interventional study of insulin aspart and human soluble insulin in Diabetes and Diabetes Mellitus, Type 1, sponsored by Novo Nordisk A/S. Completed at 80 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-04.

Primary conditionDiabetes Mellitus, Type 1Registry: Diabetes MellitusReclassifiedWhy we changed it
Registry
Diabetes Mellitus — the first condition term the registry derived for this study.
ClinicalTrials.gg
Diabetes Mellitus, Type 1
Why
  1. The study's listed conditions name Diabetes Mellitus, Type 1, a narrower term within Diabetes Mellitus.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
753
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 — 2 open to participants now, 2 under way, none of them phase 3. Insulin Aspart · Diabetes Mellitus, Type 1.

Enrollment
3rd of 87
753 · median 50
Started
1997
the only one that year
Phase 3
24 of 87
none open now
Registered
42nd of 87
by date
Lead sponsor
55 of 87
Novo Nordisk A/S

Among the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, this one is the 3rd largest by enrollment, is the only one that started in 1997, is one of 24 in phase 3, and was the 42nd registered.

Diabetes Mellitus, Type 1

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

2 of the 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1 are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing Insulin Aspart in Diabetes Mellitus, Type 1, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to evaluate the safety profile of insulin aspart in subjects with type 1 diabetes having participated in trial ANA/DCD/035.

03

Conditions studied

  • Diabetes
  • Diabetes Mellitus, Type 1

Browse trials for

04

In context

Diabetes Mellitus, Type 1 Reclassified

3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

This study's enrollment of 753 is above the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.

Browse Diabetes Mellitus, Type 1 studies →

Lead sponsor

Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.

Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.

Compared within Diabetes Mellitus, Type 1, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • The subject must have completed the six month controlled treatment period in trial ANA/DCD/035
06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
753 participants (actual)

Study arms

  • Experimental
    insulin aspart

    Drug: insulin aspart · Drug: insulin NPH

  • Active comparator
    human insulin

    Drug: human soluble insulin · Drug: insulin NPH

Interventions

  • Injected subcutaneously (s.c, under the skin) as meal time insulin

  • Injected subcutaneously (s.c, under the skin) as meal time insulin

  • Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin

07

What researchers measure

Primary outcomes

  1. Number of hypoglycaemic events

Secondary outcomes

  1. Occurrence of adverse events

  2. Incidence of hypoglycaemic episodes

  3. Standard safety parameters: Haematology and biochemistry

  4. HbA1c (glycosylated haemoglobin)

08

Study locations

80 sites
  • Novo Nordisk Investigational Site
    Graz, 8036, Austria
  • Novo Nordisk Investigational Site
    Wien, 1030, Austria
  • Novo Nordisk Investigational Site
    Wien, 1090, Austria
  • Novo Nordisk Investigational Site
    Frederiksberg, 2000, Denmark
  • Novo Nordisk Investigational Site
    Gentofte, 2820, Denmark
  • Novo Nordisk Investigational Site
    Kolding, 6000, Denmark
  • Novo Nordisk Investigational Site
    København, 2400, Denmark
  • Novo Nordisk Investigational Site
    Køge, 4600, Denmark
  • Novo Nordisk Investigational Site
    Helsinki, 00029, Finland
  • Novo Nordisk Investigational Site
    Kotka, 48210, Finland
  • Novo Nordisk Investigational Site
    Kuopio, 70210, Finland
  • Novo Nordisk Investigational Site
    Vantaa, 01400, Finland
  • Novo Nordisk Investigational Site
    Bad Neuenahr-Ahrweiler, 53474, Germany
  • Novo Nordisk Investigational Site
    Bad Oeynhausen, 32454, Germany
  • Novo Nordisk Investigational Site
    Bochum, 44789, Germany
  • Novo Nordisk Investigational Site
    Essen, 45131, Germany
  • Novo Nordisk Investigational Site
    Essen, 45138, Germany
  • Novo Nordisk Investigational Site
    Flensburg, 24939, Germany
  • Novo Nordisk Investigational Site
    Frankfurt, 60590, Germany
  • Novo Nordisk Investigational Site
    Freiburg, 79106, Germany
  • Novo Nordisk Investigational Site
    Friedrichsthal, 66299, Germany
  • Novo Nordisk Investigational Site
    Giessen, 35385, Germany
  • Novo Nordisk Investigational Site
    Haan, 42781, Germany
  • Novo Nordisk Investigational Site
    Hamburg, 20251, Germany
  • Novo Nordisk Investigational Site
    Kiel, 24103, Germany
  • Novo Nordisk Investigational Site
    Magdeburg, 39120, Germany
  • Novo Nordisk Investigational Site
    Magdeburg, 39124, Germany
  • Novo Nordisk Investigational Site
    Mainz, 55116, Germany
  • Novo Nordisk Investigational Site
    Mainz, 55131, Germany
  • Novo Nordisk Investigational Site
    Mönchengladbach, 41061, Germany
  • Novo Nordisk Investigational Site
    München, 81925, Germany
  • Novo Nordisk Investigational Site
    Oberhausen, 46145, Germany
  • Novo Nordisk Investigational Site
    Ostercappeln, 49179, Germany
  • Novo Nordisk Investigational Site
    Saarlouis, 66740, Germany
  • Novo Nordisk Investigational Site
    Schwerin, 19049, Germany
  • Novo Nordisk Investigational Site
    Stuttgart, 70184, Germany
  • Novo Nordisk Investigational Site
    Stuttgart, 70191, Germany
  • Novo Nordisk Investigational Site
    Wiesbaden, 65191, Germany
  • Novo Nordisk Investigational Site
    Wuppertal, 42117, Germany
  • Novo Nordisk Investigational Site
    Würzburg, 97070, Germany
  • Novo Nordisk Investigational Site
    Bergen, 5021, Norway
  • Novo Nordisk Investigational Site
    Haugesund, 5500, Norway
  • Novo Nordisk Investigational Site
    Oslo, 0407, Norway
  • Novo Nordisk Investigational Site
    Stavanger, 4011, Norway
  • Novo Nordisk Investigational Site
    Trondheim, 7006, Norway
  • Novo Nordisk Investigational Site
    Falun, 791 82, Sweden
  • Novo Nordisk Investigational Site
    Karlstad, 651 85, Sweden
  • Novo Nordisk Investigational Site
    Zürich, 8032, Switzerland
  • Novo Nordisk Investigational Site
    Airdrie, ML6 0JS, United Kingdom
  • Novo Nordisk Investigational Site
    Bath, BA1 3NG, United Kingdom
  • Novo Nordisk Investigational Site
    Blackburn, BB3 3LR, United Kingdom
  • Novo Nordisk Investigational Site
    Bolton, BL1 4QS, United Kingdom
  • Novo Nordisk Investigational Site
    Church Village, CF38 1AB, United Kingdom
  • Novo Nordisk Investigational Site
    Cosham, PO6 3LY, United Kingdom
  • Novo Nordisk Investigational Site
    Coventry, CV1 4FH, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH16 4SA, United Kingdom
  • Novo Nordisk Investigational Site
    Edinburgh, EH4 2XU, United Kingdom
  • Novo Nordisk Investigational Site
    Exeter, EX2 5AX, United Kingdom
  • Novo Nordisk Investigational Site
    Gillingham, ME7 5NY, United Kingdom
  • Novo Nordisk Investigational Site
    Hull, HU3 2JZ, United Kingdom
  • Novo Nordisk Investigational Site
    Inverness, IV2 3UJ, United Kingdom
  • Novo Nordisk Investigational Site
    Leicester, LE1 5WW, United Kingdom
  • Novo Nordisk Investigational Site
    London, E1 1BB, United Kingdom
  • Novo Nordisk Investigational Site
    Middlesbrough, TS5 5AZ, United Kingdom
  • Novo Nordisk Investigational Site
    Newcastle, NE7 7DN, United Kingdom
  • Novo Nordisk Investigational Site
    Northampton, NN1 5BD, United Kingdom
  • Novo Nordisk Investigational Site
    Nottingham, NG7 2UH, United Kingdom
  • Novo Nordisk Investigational Site
    Penarth, CF64 2XX, United Kingdom
  • Novo Nordisk Investigational Site
    Plymouth, PL8 8DQ, United Kingdom
  • Novo Nordisk Investigational Site
    Reading, RG51 5BS, United Kingdom
  • Novo Nordisk Investigational Site
    Rugby, CV22 5PX, United Kingdom
  • Novo Nordisk Investigational Site
    Salisbury, SP2 8BJ, United Kingdom
  • Novo Nordisk Investigational Site
    Sheffield, S5 7AU, United Kingdom
  • Novo Nordisk Investigational Site
    Southampton, SO14 OYG, United Kingdom
  • Novo Nordisk Investigational Site
    Stevenage, SG1 4AB, United Kingdom
  • Novo Nordisk Investigational Site
    Stirling, FK8 2AU, United Kingdom
  • Novo Nordisk Investigational Site
    Swansea, SA6 6NL, United Kingdom
  • Novo Nordisk Investigational Site
    Watford, WD18 0HB, United Kingdom
  • Novo Nordisk Investigational Site
    Whiston, L35 5DR, United Kingdom
  • Novo Nordisk Investigational Site
    York, YO3 7HE, United Kingdom
09

References and documents

Publications

  • Home PD, Hallgren P, Usadel KH, Sane T, Faber J, Grill V, Friberg HH. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract. 2006 Feb;71(2):131-9. doi: 10.1016/j.diabres.2005.05.015. Epub 2005 Jul 27. PubMed 16054266 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 1997, a primary completion of May 2000 and a completion of May 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 10, 2012
First posted
Oct 16, 2012
Start
Sep 1997
Primary completionActual
May 2000
CompletionActual
May 2000
Last update
Jan 4, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01707134
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 16, 2012
Start date
Sep 1997
Primary completion
May 2000
Completion
May 2000
Last update
Jan 4, 2017

Study contacts

Global Clinical Registry (GCR,1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion